Talphera (TLPH) Competitors $0.63 -0.04 (-5.94%) Closing price 04:00 PM EasternExtended Trading$0.70 +0.07 (+10.92%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TLPH vs. ANEB, CALC, SNYR, RLYB, BRNS, QTTB, BIVI, JATT, SRZN, and LEXXShould you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Anebulo Pharmaceuticals (ANEB), CalciMedica (CALC), Synergy CHC Corp. (Uplisting) (SNYR), Rallybio (RLYB), Barinthus Biotherapeutics (BRNS), Q32 Bio (QTTB), BioVie (BIVI), JATT Acquisition (JATT), Surrozen (SRZN), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry. Talphera vs. Anebulo Pharmaceuticals CalciMedica Synergy CHC Corp. (Uplisting) Rallybio Barinthus Biotherapeutics Q32 Bio BioVie JATT Acquisition Surrozen Lexaria Bioscience Anebulo Pharmaceuticals (NASDAQ:ANEB) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment. Do insiders and institutionals have more ownership in ANEB or TLPH? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 85.9% of Anebulo Pharmaceuticals shares are owned by company insiders. Comparatively, 3.2% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer ANEB or TLPH? In the previous week, Talphera had 3 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 3 mentions for Talphera and 0 mentions for Anebulo Pharmaceuticals. Talphera's average media sentiment score of 0.26 beat Anebulo Pharmaceuticals' score of 0.00 indicating that Talphera is being referred to more favorably in the news media. Company Overall Sentiment Anebulo Pharmaceuticals Neutral Talphera Neutral Which has more risk and volatility, ANEB or TLPH? Anebulo Pharmaceuticals has a beta of -1.14, suggesting that its stock price is 214% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Is ANEB or TLPH more profitable? Talphera's return on equity of -118.46% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -184.40% -158.14% Talphera N/A -118.46%-65.82% Does the MarketBeat Community believe in ANEB or TLPH? Anebulo Pharmaceuticals received 2 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 90.00% of users gave Anebulo Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAnebulo PharmaceuticalsOutperform Votes990.00% Underperform Votes110.00%TalpheraOutperform Votes7100.00% Underperform VotesNo Votes Do analysts prefer ANEB or TLPH? Anebulo Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 379.04%. Talphera has a consensus price target of $4.50, indicating a potential upside of 614.06%. Given Talphera's stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Anebulo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Talphera 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has stronger valuation & earnings, ANEB or TLPH? Anebulo Pharmaceuticals has higher earnings, but lower revenue than Talphera. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Talphera, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.30-5.57Talphera$650K16.51-$18.40M-$0.69-0.91 SummaryTalphera beats Anebulo Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Talphera News Delivered to You Automatically Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLPH vs. The Competition Export to ExcelMetricTalpheraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.73M$6.58B$5.39B$9.13BDividend YieldN/A2.96%5.37%4.00%P/E Ratio-0.9110.0188.8317.53Price / Sales16.51335.371,284.8780.48Price / CashN/A22.6336.6032.90Price / Book0.765.084.964.69Net Income-$18.40M$154.90M$117.89M$224.57M7 Day Performance8.66%2.59%2.75%3.33%1 Month Performance-0.80%1.52%3.63%5.33%1 Year Performance-28.39%5.50%27.26%22.98% Talphera Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLPHTalphera3.4328 of 5 stars$0.63-5.9%$4.50+614.1%-23.9%$10.73M$650,000.00-0.9119Analyst ForecastNews CoveragePositive NewsGap DownANEBAnebulo Pharmaceuticals2.6081 of 5 stars$1.51+3.4%$8.00+429.8%-33.8%$39.16MN/A-5.034Positive NewsCALCCalciMedica3.0392 of 5 stars$2.90-4.0%$19.33+566.7%-35.4%$39.10MN/A-2.6930Short Interest ↓Positive NewsGap UpSNYRSynergy CHC Corp. (Uplisting)N/A$4.49+7.4%N/AN/A$39.08M$26.01M0.0040Analyst ForecastPositive NewsGap UpRLYBRallybio2.6994 of 5 stars$0.92-1.9%$9.75+956.9%-39.2%$38.27M$598,000.00-0.5840Gap UpBRNSBarinthus Biotherapeutics2.7511 of 5 stars$0.94-8.7%$5.17+449.6%-67.5%$37.81M$14.97M-0.63107QTTBQ32 Bio2.3316 of 5 stars$3.10-7.2%$29.86+863.1%N/A$37.76M$-6,651,000.00-0.2239BIVIBioVie2.308 of 5 stars$2.10-5.0%$3.00+42.9%+79.2%$37.31MN/A-0.1810Gap DownJATTJATT AcquisitionN/A$2.16-0.2%N/A-58.8%$37.26MN/A0.003High Trading VolumeSRZNSurrozen3.1946 of 5 stars$11.32+1.5%$45.00+297.5%+50.6%$36.79M$10M0.0080News CoverageGap UpLEXXLexaria Bioscience2.8153 of 5 stars$2.06-4.6%$11.00+434.0%+29.3%$35.95M$464,278.00-4.387 Related Companies and Tools Related Companies Anebulo Pharmaceuticals Alternatives CalciMedica Alternatives Synergy CHC Corp. (Uplisting) Alternatives Rallybio Alternatives Barinthus Biotherapeutics Alternatives Q32 Bio Alternatives BioVie Alternatives JATT Acquisition Alternatives Surrozen Alternatives Lexaria Bioscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TLPH) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talphera, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talphera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
